Clinical trial
Study of XELOX With Cetuximab in Advanced Gastric Cancer
NCT00398398 · Asan Medical Center, Other · Completed
Key facts
| NCT number | NCT00398398 |
|---|---|
| Title | Study of XELOX With Cetuximab in Advanced Gastric Cancer |
| Official title | A Prospective Phase II Study of Cetuximab (Erbitux®) in Combination With XELOX [XELoda® (Capecitabine) and OXaliplatin] in Patients With Advanced Gastric Cancer |
| Lead sponsor | Asan Medical Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastric Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine, Oxaliplatin, Cetuximab |
| Enrollment | 44 |
| Start date | Nov 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Nov 10, 2006 |
| Last update posted | Jan 7, 2020 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: